US7157443B2 - Staphylococcus aureus exopolysaccharide and process - Google Patents
Staphylococcus aureus exopolysaccharide and process Download PDFInfo
- Publication number
- US7157443B2 US7157443B2 US10/498,070 US49807004A US7157443B2 US 7157443 B2 US7157443 B2 US 7157443B2 US 49807004 A US49807004 A US 49807004A US 7157443 B2 US7157443 B2 US 7157443B2
- Authority
- US
- United States
- Prior art keywords
- sae
- polysaccharide
- aureus
- succinate
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 0 **O[C@]1(C)C(C)(COC)O[C@@]([H])(OCC2(C)O[C@@](C)(OC)C(C)(N[1*])[C@](C)(O**)[C@]2(C)O**)C(C)(N[1*])[C@]1(C)O** Chemical compound **O[C@]1(C)C(C)(COC)O[C@@]([H])(OCC2(C)O[C@@](C)(OC)C(C)(N[1*])[C@](C)(O**)[C@]2(C)O**)C(C)(N[1*])[C@]1(C)O** 0.000 description 4
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- This invention relates to a new high molecular weight Staphylococcus aureus exopolysaccharide antigen (SAE), having the general structure of poly 1,6 ⁇ -2 amidoglucopyranoside variably substituted with N-acetyl and O-succinyl substituents, and to processes for producing it. It also pertains to vaccines made using this SAE antigen.
- SAE Staphylococcus aureus exopolysaccharide antigen
- Staphylococcus aureus and S. epidermidis are important human pathogens, accounting for the majority of nosocomial sepsis cases reported each year. Both are associated with colonization of implanted medical devices, leading to systemic bacteremia and potentially fatal conditions such as endocarditis and ventilator-associated pneumonia. Due to the increase in the number of organisms exhibiting antibiotic resistance, particularly methicillin and vancomycin resistant S. aureus strains, new avenues of protection are sought. Of particular appeal are bacterial vaccines that target surface molecules known to be important in mediating initial steps of adherence and accumulation.
- CoNS coagulase negative staphylococci
- PIA polysaccharide intercellular adhesin
- PIA isolated from S. epidermidis has been characterized by Mack et al, 1996 J. Bact. 178(1): 175–183. It is a polymer of molecular mass less than 30,000 Da, composed of ⁇ -1,6-linked glucosamine. Approximately 85% of the amino groups are substituted with N-acetate, and a minor proportion of the sugar hydroxyl groups are esterified with phosphate and succinate.
- PIA production is associated with the ica gene locus and has been demonstrated in vitro under certain defined growth conditions for several CoNS strains. Recent reports have shown that other staphylococcus species, including S. aureus, contain the ica locus. Some of these were able to elicit biofilms in culture while others did not. All of the environmental factors affecting regulation of ica are not known, and a major impediment to the development of polysaccharide-based vaccines has been the sensitivity of their expression to growth conditions. Hence, it has been difficult to show with certainty that organisms grown in vitro produce the same surface polysaccharides as those present in an in vivo infection. Finally, accurate structural characterization of polysaccharide preparations has often been hampered by residual media contaminants, and this has occasionally led to identification of what were believed to be novel antigens.
- This invention provides an isolated Staphylococcus aureus high weight exopolysaccharide antigen (SAE) having the formula
- R 1 is H and the remainder of R 1 if COCH 3 and 75–95% of R 2 is H and the remainder of R 2 if C 4 H 6 O 4, and n is such that the molecular weight is at least about 100,000 Da, preferably at least about 200,000 Da, and most preferably at least about 300,000 Da.
- approximately 45–55% of R 1 is H, and approximately 85–95% of R 2 is H. In a particularly preferred embodiment of this invention, approximately 50% of R 1 is H, and approximately 85–95% of R 2 is H.
- Another aspect of this invention is a purified Staphylococcus aureus high weight exopolysaccharide (SAE) having the formula
- R 1 is H and the remainder of R 1 is COCH 3 ; and 75–95% of R 2 is H and the remainder of R 2 is C 4 H 6 O 4 , and n is such that the molecular weight is at least about 100,000 Da, preferably at least about 200,000 Da, and most preferably at least about 300,000 Da.
- SAE is in a preparation which is at least about 75% pure, preferably at least about 80% pure, and more preferably more than about 80% pure.
- approximately 45–55% of R 1 is H, and approximately 85–95% of R 2 is H.
- approximately 50% of R 1 is H, and approximately 85–95% of R 2 is H.
- the isolated or purified SAEs of this invention may be used to make an immunogenic composition, i.e. a vaccine.
- the vaccine may be used in any animal capable of producing an immunogenic response; and this invention specifically includes human vaccines as well as those suitable for veterinary purposes.
- the immunogenic composition may contain the isolated and/or purified SAE in a physiologically acceptable salt solution. Additionally, in another embodiment, the SAE may be covalently coupled to an immunogenic protein carrier. Optionally, the SAE immunogenic composition may further comprise an immunostimulatory adjuvant.
- a further aspect of this invention is a method of inducing an immune response in an animal comprising administering one of the SAE immunogenic compositions (SAE alone, SAE conjugated to an immunogenic protein carrier, and/or in the presence of an adjuvant).
- Also provided for in this invention is a method of making a SAE compound having the formula
- R 1 is H and the remainder of R 1 is COCH 3 ; and 75–95% of R 2 is H and the remainder of R 2 is C 4 H 6 O 4 , and n is such that the molecular weight is at least about 100,000 Da, preferably at least about 200,000 Da, and most preferably at least about 300,000 Da comprising the steps of:
- the SAE compound can be subjected to a sizing chromatography step to produce a more uniformed-sized product.
- step a) comprises concentrating medium obtained from a S. aureus culture using tangential flow filtration.
- step b) comprises a diafiltration step.
- Yet another aspect of this invention relates to a high molecular weight SAE antigen produced by the process of a) concentrating medium obtained from a S. aureus culture to obtain a concentrated medium;
- the SAE compound can be subjected to a sizing chromatography step to produce a more uniformed-sized product.
- this invention also related to immunogenic compositions comprising SAEs produced by this process.
- the SAEs produced by this process may be used in a suitable vaccine formulation; alternatively they may be covalently coupled to an immunogenic protein carrier.
- FIG. 1 shows the compositional analysis of the purified SAE preparation according to this invention.
- FIG. 2 shows the HPSEC analysis of purified SAE preparations.
- a Chromatography was performed as described in the Examples.
- a 50 ⁇ l injection of pollulan standards (4–7 mg/ml) covering the M r range 47,300 to 788,000 was made and the average retention time (RT) was calculated.
- a linear plot of log 10 M r vs log 10 RT was constructed and the best fit line calculated by least squares regression.
- SAE samples a 75 ⁇ l injection of sample (1–3 mg/ml) was made and the estimated M r was determined by inputting the log 10 RT into the standard curve equation.
- b Standard and sample injections were done as for a .
- Estimated M r was determined by selecting a narrow data set from the center of the refractive index peak and assuming a dn/dc value of 0.133.
- c Values in parentheses represent a minor component peak.
- FIG. 3 shows results of hemagglutination by SAE polysaccharide forms.
- a Molecular mass determined relative to pollulan standards refer to FIG. 2 .
- Hemagglutination defined as the minimal dilution of polysaccharide required to agglutinate a 1% suspension of sheep red blood cells after 2 hr at ambient temperature.
- FIG. 4 shows characterizations of activated OMPC and SAE preparations.
- a Thiol content determined by reaction with 5,5′dithionitrobenzoic acid; protein concentration determined by modified Lowry assay. Lysine content was 0.4 ⁇ mol lys/mg protein.
- b Maleimide content determined by equivalency assay as described in Examples; glucosamine determined by HPAEC-PAD.
- c Determined by 1D 1 H NMR using pulsed field gradient diffusion filtration as described.
- FIG. 5 gives ELISA titres of native SAE after various times in mice.
- FIGS. 6A and 6B show percent survival of mice who, after vaccination, were challenged with infection.
- FIG. 6A is Native SAE-OMPC
- FIG. 6B is Sized SAE-OMPC.
- “High molecular weight” refers to a polymeric molecule having a molecular weight of at least about 100,000 Da, preferably at least about 200,000 Da, and more preferably at least about 300,000 Da.
- Isolated means that the SAE has been separated from its native organism.
- “Purified” or “Substantially pure” means that the SAE preparation which is assayed is at least about 75% pure, preferably at least about 80% pure, and more preferably more than about 80% pure.
- “Native SAE” means SAE according to this invention, but which has not undergone a sizing step; its molecular weight is much larger than “Sized” SAE; Native SAE has a molecular weight ranging from approximately 300,000 to 700,000.
- “Sized SAE” means SAE according to this invention which has undergone a sizing process, reducing its molecular weight to between 50,000 and 100,000.
- aureus mutant (strain MN8m, obtained from Brigham and Womens' Hospital) allowed purification of the antigen in sufficient quantities for physiochemical characterization and subsequent immunogenicity studies in mice.
- the McKeeney et al studies suggested that immune prophylaxis directed toward PNSG was broadly protective against both homologous and heterologous S. aureus challenge strains and that this protection was dependent on the presence of N-succinylation. Based on these studies, we sought to scale-up the production of PNSG for evaluation of its immunoprophylactic value in additional animal models. However, no antigen with the reported structure of PNSG was found.
- strain MN8m produced a high molecular mass polymer which by chemical monosaccharide analysis and NMR was shown to be made of ⁇ -1,6 glucosamine substituted with approximately 50% N-linked acetate and 10% O-linked succinate. Further, we were able to show that the previous identification of the N-linked succinate component of the glycan was an artifact of the conditions used to hydrolyze the polymer prior to its NMR characterization. Chemical and physical size reduction of the polymer could produce a molecule of molecular mass approximately 50,000 Da or less. We conclude therefore that the product of the ica locus in the S. aureus strain MN8m is SAE.
- One aspect of this invention is a method of producing a large quantity of SAE polysaccharide from S. aureus and related species, including S. epidermidis, S. carnosus and other polysaccharide-producing members of the genus.
- S. aureus In choosing the strain of S. aureus, it is desirable to use an overproducing strain, such as MN8, but other strains may be used. Fermentation conditions are often more important for achieving high productivity, and may be even more important than is choice of strain.
- a “complex” medium is any culture medium which contains one or more undefined components, such as a plant peptone, microbial extract or an animal source component.
- FIG. 1 presents the results of compositional analysis for various forms of the polysaccharide.
- one aspect of this invention is a process for producing SAE in a Staphylococcus sp. comprising the steps of culturing the Staphylococcus on a complex medium for a time period of up to twenty-four hours, and harvesting the resultant SAE.
- the media should preferably contain soy peptone and/or yeast extract. Ranges for these ingredients may vary depending on the requirements of the individual organism being cultured, but in general the soy peptone may be present in amounts from approximately 5–35 g/liter, preferably about 10–30 g/liter; and more preferably about 20 g/liter.
- yeast extract ranges are from approximately 20–60 g/liter, preferably about 30–50 g/liter and more preferably about 45–50 g/liter.
- salts such as NaCl, or KCl, 0.5–15 g/liter, preferably about 5 g/liter
- buffers such as potassium phosphate dibasic or other buffers known in the art to be useful in culture media, 1–5 g/liter, preferably about 2.5 g/liter) which provide a pH range from about 6.5 to 7.5.
- an antifoam agent such as U CON LB625 (0.01–5 ml, preferably about 0.5 ml) or a silicone based antifoam agent.
- succinic acid at approximately 1 g/liter
- sodium succinate approximately 1 g/liter
- other supplements commonly used in media preparation and which can be used by the bacteria as a carbon source and/or a buffer
- carbon sources including any type of hexose and most disaccharides, preferably dextrose, should be present at about a 1% concentration.
- the time of culture can vary, and is typically about 18 to 24 hours, although an extend time may be used.
- the culture should provide agitated cultivation conditions, the degree of aeration can be manipulated using various shaker speeds, flask configuration and culture media volumes. Such culture parameters are well known in the art.
- PNSG antigen from S. epidermidis and S. aureus indicated the need for harsh extraction conditions utilizing strong acid (5N HCl) and subsequent low pH (pH 2.5) processing steps to produce a soluble product.
- One aspect of this invention is the discovery that these harsh extraction conditions are unnecessary and large quantities of polysaccharide can be purified from culture supernatant using a process comprising the steps of membrane ultrafiltrations (or size exclusion chromatography), enzymatic treatment for selective contaminant removal (or chromatography followed by solvent precipitation), and an optional chromatographic polishing step or anion-exchange chromatography.
- the polishing step removes low abundance acidic contaminants by, for example, anion exchange chromatography or by HF-treatment.
- high salt means 1.5 to 3M sodium chloride or potassium chloride, preferably about 2 M sodium chloride, or if another salt is used, the concentration of that salt which would be the equivalent of 1.5 to 3M sodium chloride.
- a “low pH” means pH 2.0–3.0, preferably about 2.5.
- the protocol of this invention resulted in overall process yields of approximately 400 mg/L culture fluid which was significantly higher than the 0.5 to 2 mg/L reported for S. aureus strain pCN27 by McKenny (supra).
- HPAEC-PAD pulsed amperometric detection
- Native SAE is composed of a ⁇ -1,6-linked homopolymer of glucosamine residues of which approximately 57% were substituted with acetate. No succinylation of amino groups was observed. The low amount of succinate (10%) observed by both methods was shown to be linked to sugar hydroxyl groups based on a strong downfield shift of the proton at the substituted position as well as its liability of the O-substituted esters to mild base treatment.
- the SAE obtained was highly purified with the major contaminant being teichoic acid (2–5%) as identified by detection of glycerolphosphate.
- UV absorption spectroscopy revealed the presence of a 260 nm-absorbing impurity suggestive of nucleic acids.
- SAE with stripping conditions SM NaOH, 37° C., 18 h; neutralization and diafiltration
- results from agarose electrophoresis with specific stain detection identified the contaminant as DNA.
- the level of presumptive DNA in the powder was 3–5% (w/w) based on 260 nm absorbance measurements. Teichoic acid impurity was detected by NMR based on polyphosphoglycerol content, and accounted for approximately 5% of the product by mass.
- BF treatment of the product was effective at removing glycerolphosphate-contaminants, but this procedure also resulted in loss of O-succinylation. Since the NMR data indicated very little change in the amount of free glucosamine amino groups before and after HF treatment, this implies that BF-SAE is a more positively charged species.
- Anion exchange chromatography (AEC) provided a chemically mild alternative to BF and was highly effective in reducing teichoic acid and DNA to non-detectable levels while yielding a high product recovery of 80–90%.
- AEC-SAE retained its original chemical composition including maintenance of O-succinylation.
- the higher value observed by NMR resulted from the supernatant of incomplete solubilized AEC-SAE in D 2 O after lyophilization. Since the succinate was completely liberated by base treatment and some polysaccharide was invisible to NMR due to its poor solubility, this resulted in the apparently higher succinate ratio.
- the percentage of O-substituted succinic acid was determined on the sample in alkaline solution where O-succinate was hydrolyzed to free succinate.
- the well resolved peak of free succinate at approximately 2.39 ppm was integrated, and its ratio over polysaccharide repeating units, represented by the anomeric peaks (4.3–4.6 ppm) was calculated as O-succinate percentage.
- FIG. 2 shows the estimated molecular masses of the various forms determined by each method. In all cases the MALLS values were roughly twice as high as those determined by elution time relative to standards. Light scattering measurements are sensitive to low abundance contaminants, and even very low concentrations of a high M r species can seriously skew results toward the high end limit of mass. To minimize these effects, sharp cuts were taken at the apex of the refractive index peak, but bleed-in from the high M r components was still possible.
- Native SAB was isolated as a high M r polymer of greater than 300,000 Da.
- AEC was used for removing non-covalently electrostatically associated acidic contaminants.
- Treatment of native SAE with HF resulted in considerable hydrolysis with a concomitant size reduction of 5–10 fold.
- Physical sizing of AEC-SAE by sonication was employed in order to control the total reduction obtained and to avoid chemical alteration of the antigen.
- the conditions employed resulted in a preparation with M r comparable to HF-treated material. Based on analytical HPSEC of the intermediate sonication timepoints the reduction process was fairly linear. It is unclear why the AEC-sized material contained a low abundance peak of very high M r . It is conceivable that under the inputted energy conditions a small amount of radical-induced polymerization may have proceeded as a minor side reaction.
- FIG. 3 summarizes the minimum concentration of each SAE form required to agglutinate red blood cells.
- the HF-treated SAE showed the poorest ability to hemagglutinate, requiring a four to eight-fold higher concentration for hemagglutination than any of the other preparations.
- HF-treated SAE was both more positively charged than the other forms and had a low molecular mass.
- FIG. 4 summarizes the analytical characterization of conjugates and activated intermediates.
- the large, particulate nature of OMPC allowed the use of ultracentrifugation for removal of excess reagents and unconjugated polysaccharide.
- the thiolation conditions used produced an activated OMPC with 43% of theoretical surface-accessible lysines derivatized.
- the product was stable with a loss of less than 10% of sulfhydryl reactivity over 70 hr at 4° C.
- compositional analysis indicated that these targets were achieved for both intact (11%) and sized (13%) preparations.
- Stringent washing conditions using high salt and detergent were found to be necessary to effect removal of more than 95% of unconjugated polysaccharide.
- the conjugates were adsorbed to alum adjuvant at 0.5 mg/ml at which concentration they were greater than 99% adsorbed.
- Routine stability monitoring of the bulk alum product was performed by pelleting an aliquot and measuring the protein in the supernatant fraction. No detectable protein was observed after 45 days at 4° C. storage.
- compositions comprising the SAEs of the present invention may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier examples include OMPC, or alum (adsorbed onto aluminum hydroxide) Others may be found in Remington's Pharmaceutical Sciences.
- OMPC OMPC
- alum adsorbed onto aluminum hydroxide
- Vaccine compositions of this invention are administered to an individual in amounts sufficient to prevent Staphylococcus infections.
- the effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
- the compositions will be administered in dosages ranging from about 0.5 ⁇ g to about 250 ⁇ g.
- the vaccines may be administered by a variety of routes, such as orally, parenterally, subcutaneously, mucosally or intramuscularly.
- the vaccine may be used in dosage forms such as capsules, suspensions, elixirs, or liquid solutions.
- the vaccine may be formulated with an immunologically acceptable carrier.
- the vaccines are administered in therapeutically effective amounts, that is, in amounts sufficient to generate an immunologically protective response.
- the vaccine may be administered in single or multiple doses.
- Culture broth was prepared by dissolving 300 g soy peptone, 75 g NaCl, and 37.5 g potassium phosphate dibasic in 4 L pyrogen free water (PFW). 1.5 L of dissolved Yeast Extract, ultrafiltrate grade (YEU) was added to the mixture and the volume was adjusted to 14.4 L with PFW (YEU final concentration of 31.5 gm/L). UCON LB625 antifoam (7.5 ml) was added and the medium was supplemented with 1 g/L succinic acid and 1 g/L sodium succinate. Broth was sterilized at 123° C. for 30 min after which sterile dextrose was added to a final concentration of 1%.
- PFW pyrogen free water
- the flasks were harvested for inoculum preparation.
- the soy peptone/YEU media was inoculated with 40 ml MN8m inoculum.
- the culture was agitated and sparged with air to maintain dissolved oxygen at 30%. Temperature was maintained at 37° C., and pH was maintained at 7 by addition of sterile 30% NaOH. Growth was terminated when NaOH ceased to be required to maintain pH 7.
- the pH was adjusted to 5 with 50% acetic acid and MgCl 2 was added to 0.1M.
- the culture was heated to 60° C. and held for 90 min.
- the inactivated culture was centrifuged at 13,600 ⁇ g for 10 min and supernatant was retained for further processing.
- Conditioned supernatant (11.2 L) was clarified by filtration using Suporcap-100 0.8/0.2 micron cartridges (Pall Gelman, Ann Arbor, Miss.) and then concentrated by tangential flow filtration (TFF) using a 500K molecular weight cutoff (MWCO) hollow-fiber membrane cartridge (AIG Technologies, Needham, Mass.) to a volume of 700 mL. Following concentration, the retentate fraction was diafiltered against. 8 volumes of distilled deionized (DI) water. The retentate was adjusted to 5 mM Tris-HCl, pH 8, 2 mM CaCl 2 , and 2 mM MgCl 2 .
- DI distilled deionized
- Proteinase K 14 mg was added and the mixture was allowed to incubate for 16 hours at 20° C.
- the digestion reaction was adjusted to 2M NaCl and concentrated to 700 mL by TFF as previously described.
- the retentate was successively diafiltered against 8 volumes of 2M NaCl, 8 volumes of Low pH Buffer (25 mM sodium phosphate, pH 2.5, 0.1M NaCl), and 10 volumes of DI water, after which it was concentrated to a final volume of 340 mL.
- the concentrate was shell-frozen in pre-weighed bottles and lyophilized to dryness to generate native SAE antigen.
- Native SAE (101 mg) was dissolved in DI water at 5 mg/ml. An equal volume of 48% HF was added after which the sample was mixed by inversion and incubated at 4° C. for 25 hr. The reaction was diluted with an equal volume of DI water and the pH was adjusted to neutrality by addition of 50% NaOH. The sample was dialyzed against hot DI water (65° C.) for 22 hr using 8 K MWCO tubing. It was then dialyzed a further 24 hr against 2 changes of DI water at ambient temperature. The reaction mixture was shell-frozen in pre-weighed bottles and lyophilized to dryness.
- Polysaccharide analysis was carried out on a high field NMR instrument. To simplify the spectrum due to O-substituted succinate, the sample was dissolved in D 2 O at pH ⁇ 12. DSS-d6 was spiked in the sample as a reference of chemical shift (0 ppm). The spectrum was acquired at 20° C. The spectral width was at least 6 ppm to cover all the interested proton peaks.
- the percentages of GlcNH 2 and GlcNAc were determined from the peak integration of anomeric protons on these residues.
- the O-substitution percentage was based on the ratio of the peak integration of liberated succinate and anomeric proton.
- the anomeric configuration of sugar residues was determined by measuring the 3 JH1H2 coupling constant.
- Glycerophosphate and succinate analyses were performed at room temperature on a Ionpac AS 11 column (4 mm i.d. ⁇ 250 mm) at a flow rate of 1 ml/min using the elution scheme: (a) isocratic at 4 mM NaOH for 5 min; (b) gradient from 4 to 10 mM NaOH in 10 min; (c) step gradient from 10 to 20 mM NaOH in 0.1 min; (d) wash at 50 mM NaOH for 14 min; (e) restoring of the isocratic condition at 4 mM NaOH for 10 min.
- HPSEC High Performance Size Exclusion Chromatography
- Relative molecular weights of polysaccharide preparations were determined on a Alliance 2690 HPLC system (Waters, Milford, Mass.) using two Waters ULTRAHYDROGEL Linear columns (7.8mm i.d. ⁇ 300 mm) linked in series behind a guard column and a 250 Psi flow restrictor. Chromatography was performed in 0.1 M sodium phosphate pH 7.2 buffer containing 0.05% sodium azide at a flow rate of 0.5 ml/min. Detection was by refractive index using a Waters 410 differential refractometer.
- Pollulan molecular weight markers (Polymer Laboratories, Amherst, Mass.) were used to calibrate the system Multi-angle laser light scattering (MALLS) data was generated using a dual angle Precision Detectors PD2000DLS system calibrated with the 47,300 Da pollulan standard.
- MALLS Multi-angle laser light scattering
- S. epidennidis strain RP62a cells were grown overnight on TSA plates and suspensions from these plates were subcultured for 3–5 hours in TS broth in shake flasks at 37° C. Cells were harvested, washed once in PBS, and suspended in PBS to an OD 650 nm of 1.
- a 1% sheep red blood cell (SRB) suspension was made by reconstituting lyophilized SRB (Sigma, St. Louis, Mo.) in PBS, 1% BSA. Bacterial suspension (50 ⁇ l) was added to a 96 well microtiter plate, and subsequent 2-fold dilutions of bacteria were made in PBS. Then 50 ⁇ l of 1% SRB was added to each well and the plate was incubated without mixing at room temperature for 2 hours before visual examination.
- OMPC carrier protein was activated by thiolation of available lysine residues using a standard technique with minor modifications. Briefly, OMPC (70 mg) was pelleted by centrifugation at 289,000 ⁇ g for 90 min and resuspended at 10 mg/mL in 0.1M sodium borate buffer, pH 11.3 using a Dounce homogenizer. For thiolation, 40 mg of EDTA and 8 mg of DTT were dissolved in 1.4 mL pH 11 buffer and 63 mg of N-acetyl homocysteine thiolactone was dissolved in 0.7 mL H 2 O. The solutions were added to the OMPC and the reaction mixture was incubated for 2 hrs under N 2 at room temperature.
- the thiolated OMPC was pelleted as above, washed with 20 mM HEPES, 2 mM EDTA, 150 mM NaCl, pH 7.3, (HEPES/EDTA) and repelleted. The pellet was resuspended at 10 mg/mL in HEPES/EDTA and the thiolated OMPC was centrifuged at 1,000 ⁇ g for 5 min at 4° C. to pellet any aggregated material.
- Polished or polished and sized SAE was activated for conjugation by introduction of a maleimide group using the heterobifunctional reagent sulfo-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, sSMCC (Pierce, Rockford, Ill.). Solid sSMCC was added to the polysaccharide dissolved in water at a 5-fold molar excess over SAE free glucos amine (as determined by NMR). The reaction was adjusted to pH 7.8 by addition of HEPPS to a final concentration of 35 mM. The reaction was incubated in the dark at room temperature for 3 hours.
- sSMCC heterobifunctional reagent sulfo-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
- Solid sSMCC was added to the polysaccharide dissolved in water at a 5-fold molar excess over SAE free
- reaction mix was concentrated and diafiltered against HBS using a 10 K Pellicon flat sheet membrane.
- Maleimide incorporation was determined by quantitation of thiol consumption.
- Activated polysaccharides were snap frozen and stored at ⁇ 70° C. prior to conjugation.
- polysaccharides were thawed and mixed with thiolated OMPC at a 0.5 to 1 molar ratio of maleimide to sulfhydryl.
- the pH was adjusted to 7 by addition of HBS and reactions were incubated for 15 to 20 hr at room temperature in the dark.
- iodoacetamide was added at a 10 fold molar excess over total sulfhydryl, and the reactions were incubated for 15 to 20 hr at room temperature in the dark.
- N-acetyl-cysteamine was added at a 5-fold molar excess over iodoacetamide and incubated as above.
- Conjugates were adsorbed onto alum adjuvant at a final concentration of 0.5 mg/ml by mixing a 2 ⁇ stock and 2 ⁇ alum at room temperature for 45 minutes.
- the alum-adsorbed bulk was formulated for animal studies by preparing vaccine stocks at 80, 8, 0.8, and 0.08 ⁇ g/ml polysaccharide.
- Bulk alum product was diluted with 1 ⁇ alum diluent to achieve the final desired concentrations.
- mice (4–5 weeks old) were rested for one week and then immunized with 0.05 ⁇ l into backs of both thigh muscles with Native SAE-OMPC and Sized SAE-OMPC formulated in 1 ⁇ Merck Aluminum Adjuvant.
- the animals were divided into 8 groups of 25 mice and each group received 8, 0.8, 0.08 or 0.008 ⁇ g/mouse of either Native or Sized versions of the SAE-OMPC conjugated antigen adsorbed onto 1 ⁇ Merck Aluminum Adjuvant.
- a separate group of 25 mice were immunized with 1 ⁇ Merck Aluminum Adjuvant alone.
- the groups were immunized with the antigens on Day 0 and Day 14. Blood from a subset of animals was collected at Day ⁇ 2, Day 21 and day 28.
- the animals were challenged with 9.88 ⁇ 10 8 CFU of S. epidermidis strain RP62A by IP injection. The number of animals that survived the challenge was followed for 7 days, and is shown in FIGS. 6A and 6B .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
wherein 40–60% of R1 is H and the remainder of R1 if COCH3 and 75–95% of R2 is H and the remainder of R2 if C4H6O4, and n is such that the molecular weight is at least about 100,000 Da, preferably at least about 200,000 Da, and most preferably at least about 300,000 Da.
wherein 40–60% of R1 is H and the remainder of R1 is COCH3; and 75–95% of R2 is H and the remainder of R2 is C4H6O4, and n is such that the molecular weight is at least about 100,000 Da, preferably at least about 200,000 Da, and most preferably at least about 300,000 Da. Preferably the SAE is in a preparation which is at least about 75% pure, preferably at least about 80% pure, and more preferably more than about 80% pure.
wherein 40–60% of R1 is H and the remainder of R1 is COCH3; and 75–95% of R2 is H and the remainder of R2 is C4H6O4, and n is such that the molecular weight is at least about 100,000 Da, preferably at least about 200,000 Da, and most preferably at least about 300,000 Da comprising the steps of:
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/498,070 US7157443B2 (en) | 2001-12-11 | 2002-12-06 | Staphylococcus aureus exopolysaccharide and process |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34675501P | 2001-12-11 | 2001-12-11 | |
US60346755 | 2001-12-11 | ||
US35594102P | 2002-02-11 | 2002-02-11 | |
PCT/US2002/039079 WO2003053462A2 (en) | 2001-12-11 | 2002-12-06 | Staphylococcus aureus exopolysaccharide and process |
US10/498,070 US7157443B2 (en) | 2001-12-11 | 2002-12-06 | Staphylococcus aureus exopolysaccharide and process |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040259838A1 US20040259838A1 (en) | 2004-12-23 |
US7157443B2 true US7157443B2 (en) | 2007-01-02 |
Family
ID=26995003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/498,070 Expired - Fee Related US7157443B2 (en) | 2001-12-11 | 2002-12-06 | Staphylococcus aureus exopolysaccharide and process |
Country Status (7)
Country | Link |
---|---|
US (1) | US7157443B2 (en) |
EP (1) | EP1455817B1 (en) |
JP (1) | JP2005532415A (en) |
AT (1) | ATE419005T1 (en) |
CA (1) | CA2469132A1 (en) |
DE (1) | DE60230670D1 (en) |
WO (1) | WO2003053462A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040175731A1 (en) * | 2002-11-12 | 2004-09-09 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
US20050118198A1 (en) * | 2002-11-12 | 2005-06-02 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
WO2009155059A2 (en) * | 2008-05-28 | 2009-12-23 | Trustees Of Tufts College | Polysaccharide composition and methods of isolation of the emulsion stabilizing cationic polyelectrolytic polysaccharide |
US20110150880A1 (en) * | 2008-07-21 | 2011-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
WO2012150603A1 (en) * | 2011-05-04 | 2012-11-08 | Serum Institute Of India Ltd. | Removal of "polyose type" teichoic acid contaminants from bacterial polyoses |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US7252828B2 (en) | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
AU2005236068C1 (en) | 2004-04-21 | 2012-08-30 | Beth Israel Deaconess Medical Center, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
EP2305294B1 (en) | 2004-09-22 | 2015-04-01 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
AU2006213662B2 (en) * | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
BRPI0615049B1 (en) | 2005-08-24 | 2023-04-25 | Immunogen, Inc | PROCESS FOR THE PREPARATION OF AN ANTIBODY- MAITANSINOID CONJUGATE |
AR060188A1 (en) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | CONJUGATION PROCEDURE |
EP2476434A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8084443B2 (en) | 2007-10-01 | 2011-12-27 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
WO2010042481A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
KR20170102039A (en) | 2009-04-03 | 2017-09-06 | 유니버시티 오브 시카고 | Compositions and methods related to Protein A (SpA) variants |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
DK2437790T3 (en) | 2009-06-03 | 2019-05-20 | Immunogen Inc | conjugation |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2508885B1 (en) * | 2009-11-30 | 2017-03-08 | Sekisui Medical Co., Ltd. | Homogenous measurement method and measuring reagent |
US8808699B2 (en) | 2010-04-05 | 2014-08-19 | The University Of Chicago | Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response |
AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
WO2012034067A1 (en) | 2010-09-09 | 2012-03-15 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
US8795673B2 (en) | 2011-03-29 | 2014-08-05 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
WO2013112916A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
NZ702285A (en) | 2012-04-26 | 2016-07-29 | Univ Chicago | Staphylococcal coagulase antigens and methods of their use |
CN105209592A (en) | 2012-10-04 | 2015-12-30 | 伊缪诺金公司 | Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates |
WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695624A (en) * | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
WO1993014784A1 (en) | 1992-02-04 | 1993-08-05 | Consejo Superior Investigaciones Cientificas | Vaccine against staphylococci and preparation thereof |
US5770208A (en) | 1996-09-11 | 1998-06-23 | Nabi | Staphylococcus aureus B-linked hexosamine antigen |
WO2000003745A2 (en) | 1998-07-15 | 2000-01-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
US20020119166A1 (en) | 1998-07-15 | 2002-08-29 | Gerald Pier | Polysaccharide vaccine for staphylococcal infections |
-
2002
- 2002-12-06 WO PCT/US2002/039079 patent/WO2003053462A2/en active Search and Examination
- 2002-12-06 DE DE60230670T patent/DE60230670D1/en not_active Expired - Lifetime
- 2002-12-06 AT AT02790044T patent/ATE419005T1/en not_active IP Right Cessation
- 2002-12-06 EP EP02790044A patent/EP1455817B1/en not_active Expired - Lifetime
- 2002-12-06 JP JP2003554219A patent/JP2005532415A/en not_active Withdrawn
- 2002-12-06 US US10/498,070 patent/US7157443B2/en not_active Expired - Fee Related
- 2002-12-06 CA CA002469132A patent/CA2469132A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695624A (en) * | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
WO1993014784A1 (en) | 1992-02-04 | 1993-08-05 | Consejo Superior Investigaciones Cientificas | Vaccine against staphylococci and preparation thereof |
US5770208A (en) | 1996-09-11 | 1998-06-23 | Nabi | Staphylococcus aureus B-linked hexosamine antigen |
WO2000003745A2 (en) | 1998-07-15 | 2000-01-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
US20020119166A1 (en) | 1998-07-15 | 2002-08-29 | Gerald Pier | Polysaccharide vaccine for staphylococcal infections |
Non-Patent Citations (4)
Title |
---|
Abeygunawardana et al., "Determination of the Chemical Structure of Complex Polysaccharides by Heteronuclear NMR Spectroscopy", Advances in Biophysical Chemistry, vol. 3, pp. 199-249 (1993). |
Mack, Dietrich et al., "The Intercellular Adhesin Involved in Biofilm Accumulation of Staphylococcus epidermidis Is a Linear Beta-1,6-Linked Glucosaminoglycan: Purification and Structural Analysis", Journal of Bacteriology, vol. 178, No. 1, pp. 175-183 (1996). |
McKenney, David et al., "Broadly Protective Vaccine for Staphylococcus aureus Based on an in Vivo-Expressed Antigen", Science, vol. 284, pp. 1523-1527 (1999). |
McKenney, David et al., "The ica Locus of Staphylococcus epidermidis Encodes Production of the Capsular Polysaccharide/Adhesin", Infection and Immunity, vol. 66, No. 10, pp. 4711-4720 (1998). |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040175731A1 (en) * | 2002-11-12 | 2004-09-09 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
US20050118198A1 (en) * | 2002-11-12 | 2005-06-02 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
US10919956B2 (en) * | 2002-11-12 | 2021-02-16 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
US7723087B2 (en) | 2002-11-12 | 2010-05-25 | The Brigham And Women's Hospital, Inc. | Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof |
US20110206772A1 (en) * | 2008-05-28 | 2011-08-25 | Trustees Of Tufts College | Polysaccharide composition and methods of isolation of the emulsion stabilizing cationic polyelectrolytic polysaccharide |
WO2009155059A3 (en) * | 2008-05-28 | 2010-06-10 | Trustees Of Tufts College | Polysaccharide composition and methods of isolation of the emulsion stabilizing cationic polyelectrolytic polysaccharide |
US8609835B2 (en) | 2008-05-28 | 2013-12-17 | Trustees Of Tufts College | Polysaccharide composition and methods of isolation of the emulsion stabilizing cationic polyelectrolytic polysaccharide |
WO2009155059A2 (en) * | 2008-05-28 | 2009-12-23 | Trustees Of Tufts College | Polysaccharide composition and methods of isolation of the emulsion stabilizing cationic polyelectrolytic polysaccharide |
US20110150880A1 (en) * | 2008-07-21 | 2011-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
US8492364B2 (en) | 2008-07-21 | 2013-07-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides |
US9474806B2 (en) | 2008-07-21 | 2016-10-25 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
US10034927B2 (en) | 2008-07-21 | 2018-07-31 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
US11123416B2 (en) | 2008-07-21 | 2021-09-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
WO2012150603A1 (en) * | 2011-05-04 | 2012-11-08 | Serum Institute Of India Ltd. | Removal of "polyose type" teichoic acid contaminants from bacterial polyoses |
Also Published As
Publication number | Publication date |
---|---|
WO2003053462A2 (en) | 2003-07-03 |
ATE419005T1 (en) | 2009-01-15 |
DE60230670D1 (en) | 2009-02-12 |
JP2005532415A (en) | 2005-10-27 |
EP1455817A2 (en) | 2004-09-15 |
WO2003053462A3 (en) | 2003-09-04 |
CA2469132A1 (en) | 2003-07-03 |
EP1455817B1 (en) | 2008-12-31 |
EP1455817A4 (en) | 2005-11-30 |
US20040259838A1 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7157443B2 (en) | Staphylococcus aureus exopolysaccharide and process | |
US7491517B2 (en) | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 | |
Joyce et al. | Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureus | |
EP1051506B1 (en) | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines | |
EP0549617B1 (en) | Improved vaccine compositions | |
FI110164B (en) | Process for Preparation of an Oligosaccharide by Depolymerization of an Antigenic Polysaccharide | |
US20100063270A1 (en) | Purification of Streptococcal Capsular Polysaccharide | |
JPH05148157A (en) | Polysaccharide antigen from pneumonia streptococcus | |
JP2016047852A (en) | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides | |
JP2008523142A (en) | Conjugate carbohydrate vaccine containing peptidoglycan | |
KR101161033B1 (en) | Process for producing a capsular polysaccharide for use in conjugate vaccines | |
CN104487086B (en) | Non-animal derived nonalcoholic vaccine composition and preparation method thereof | |
CA3110134A1 (en) | Escherichia coli compositions and methods thereof | |
EP0528635B1 (en) | Process for converting lipid-containing polysaccharide into lipid-free polysaccharide | |
CA2645365C (en) | Type 5 and type 8 capsular polysaccharides of superproducing staphylococcus aureus strains | |
EP2705853B1 (en) | Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same | |
US5314811A (en) | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide | |
RU2407792C1 (en) | METHOD FOR PRODUCING IgAl-PROTEASE FROM SEROGROUP A NEISSERIA MENINGITIDIS AND RELATED IMMUNOGENIC PREPARATION | |
RU2159128C1 (en) | Oral chemical vaccine for protecting against cholera | |
CN106109486A (en) | A kind of compositions and preparation method and application | |
Bei et al. | Re-N-acetylation of group B Streptococcus type Ia capsular polysaccharide improves the immunogenicity of glycoconjugate vaccines | |
EA044044B1 (en) | IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK & CO., INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOYCE, JOSEPH G.;COOK, III, JAMES C.;ABEYGUNAWARDANA, CHITRANANDA;AND OTHERS;REEL/FRAME:018527/0637;SIGNING DATES FROM 20030213 TO 20030220 |
|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:MERCK & CO., INC.;REEL/FRAME:023861/0349 Effective date: 20091102 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: SCHERING CORPORATION, NEW JERSEY Free format text: MERGER;ASSIGNOR:MERCK SHARP & DOHME CORP.;REEL/FRAME:028850/0515 Effective date: 20120426 |
|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING CORPORATION;REEL/FRAME:028866/0511 Effective date: 20120502 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20150102 |